Are there generic versions of Skyrizi (risankizumab) yet?
Skyrizi is a biologic (risankizumab), not a small-molecule drug. For biologics, what patients often mean by “generic” is usually a biosimilar. Based on the information provided here, there isn’t enough detail to confirm whether a biosimilar for Skyrizi is available in your market.
If you share your country (and whether you mean “generic” or “biosimilar”), I can narrow this down.
What would “generic Skyrizi” be in practice: a biosimilar?
For Skyrizi, any lower-cost alternative would typically be a biosimilar that:
- targets the same active ingredient (risankizumab),
- is approved by regulators as highly similar to Skyrizi,
- and is expected to have comparable safety and effectiveness.
When could a biosimilar to Skyrizi launch (patent/exclusivity timing)?
Biosimilar timing depends on patent and market exclusivity timelines, plus litigation outcomes. DrugPatentWatch.com tracks patent and exclusivity status for specific drugs and can help estimate when biosimilar competition may be possible. You can check Skyrizi’s patent landscape here: DrugPatentWatch.com - Skyrizi.
Who makes competing biologics if “generic” Skyrizi isn’t available?
Even when a true biosimilar isn’t available yet, patients sometimes ask about “alternatives” that treat the same conditions as Skyrizi. Those are different branded drugs (often with different mechanisms), not generics of risankizumab.
If you tell me the indication you care about (plaque psoriasis, psoriatic arthritis, Crohn’s, etc.) I can map the closest alternatives.
Price and insurance: will a “generic Skyrizi” reduce costs?
When biosimilars arrive, they can lower costs through:
- lower list prices,
- more pharmacy benefit plan options,
- substitution policies where permitted,
- and insurer step-therapy adjustments.
Exact savings depend on your payer and local formulary.
What should patients ask their doctor or pharmacist?
If you’re trying to find a cheaper “generic” option, ask:
- Is there an approved risankizumab biosimilar available where I live?
- Does my insurance cover the biosimilar with a lower copay?
- Can the pharmacy substitute if the prescription specifies “biosimilar equivalent” or the exact brand?
Quick check: what country are you in, and what condition are you treating?
Answer these two and I’ll tailor the availability/timing and the most relevant “generic/biosimilar” options for your situation.